Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). VistaGen Therapeutics's share price for the quarter that ended in Dec. 2021 was $1.95. VistaGen Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2021 was 206.51 Mil. Therefore, VistaGen Therapeutics's market cap for the quarter that ended in Dec. 2021 was $402.69 Mil.
VistaGen Therapeutics's quarterly market cap
declined
from Jun. 2021 ($603.21 Mil) to Sep. 2021 ($538.20 Mil) and
declined
from Sep. 2021 ($538.20 Mil) to Dec. 2021 ($402.69 Mil).
VistaGen Therapeutics's annual market cap
declined
from Mar. 2019 ($54.56 Mil) to Mar. 2020 ($21.65 Mil) but then
increased
from Mar. 2020 ($21.65 Mil) to Mar. 2021 ($384.71 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. VistaGen Therapeutics's Enterprise Value for Today is $136.30 Mil.
VistaGen Therapeutics Market Cap Historical Data
The historical data trend for VistaGen Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
VistaGen Therapeutics Annual Data
Trend
Mar12
Mar13
Mar14
Mar15
Mar16
Mar17
Mar18
Mar19
Mar20
Mar21
Market Cap
17.32
21.33
54.56
21.65
384.71
VistaGen Therapeutics Quarterly Data
Mar17
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Market Cap
269.01
384.71
603.21
538.20
402.69
Competitive Comparison
For the Biotechnology subindustry, VistaGen Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VistaGen Therapeutics Market Cap Distribution
For the Biotechnology industry and Healthcare sector, VistaGen Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where VistaGen Therapeutics's Market Cap falls into.
VistaGen Therapeutics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
VistaGen Therapeutics's Market Cap for the fiscal year that ended in Mar. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VistaGen Therapeutics (NAS:VTGN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companyÂ’s debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
VistaGen Therapeutics Market Cap Related Terms
Thank you for viewing the detailed overview of VistaGen Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.06(5.41%) Volume: 1,357,425 8:08PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:VTGN has been successfully added to your 
